PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
0.0150
0.0000 (0.00%)
At close: 09:59AM EDT
Stock chart is not supported by your current browser
Previous Close0.0150
Open0.0000
Bid0.0100 x 0
Ask0.0200 x 0
Day's Range0.0150 - 0.0150
52 Week Range0.0100 - 0.3000
Volume0
Avg. Volume19,178
Market Cap583,638
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 08, 2016
1y Target EstN/A
  • CNW Group

    IIROC Trade Resumption - PILL

    Trading resumes in:

  • ACCESSWIRE

    Canntab Announces Corporate Update

    Canntab Therapeutics Limited (CSE:PILL)(OTCQB:CTABF)(FRA:TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing an update on several matters impacting the Company.

  • CNW Group

    IIROC Trading Halt - PILL

    The following issues have been halted by IIROC:

  • CNW Group

    CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product delivery of our unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (the "NSLC").

  • CNW Group

    CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO

    Canntab Therapeutics Limited (CSE: PILL.CN)(OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022.

  • CNW Group

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnership